Advances in the treatment of gastrointestinal stromal tumours

Annals of Oncology

Volumn 18, Issue SUPPL. 10, 2007, Pages

  Judson, Ian ^a   Demetri, G ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

GIST; Imatinib; KIT; PDGFR; Sunitinib

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; IMATINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; BLOOD TOXICITY; CANCER RESISTANCE; CLINICAL TRIAL; CONFERENCE PAPER; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENOTYPE; HEART DISEASE; HUMAN; HYPOTHYROIDISM; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR GROWTH; DISEASE COURSE; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; PIPERAZINES; PYRIMIDINES; PYRROLES;

EID: 45949105461     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm410     Document Type: Conference Paper

References (31)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12.
2. Nilsson B, Bumming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005; 103: 821-829.
3. Joensuu H, Kindblom LG. Gastrointestinal stromal tumors - a review. Acta Orthop Scand 2004; 75 (Suppl): 62-71.
4. Judson I. Gastrointestinal stromal tumours (GIST): Biology and treatment. Ann Oncol 2002; 13 (Suppl 4): 287-289.
5. Dematteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.
6. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
7. Rubin BP, Singer S, Tsao C et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118-8121.
8. D'Amato G, Steinert DM, McAuliffe JC et al. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005; 12: 44-56.
9. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 5708-5710.
10. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349.
11. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
12. Rankin C, von Mehren M, Blanke CD et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST- phase III sarcoma group study S0033. J Clin Oncol 2004; 22.
13. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004; 364: 1127-1134.
14. Zalcberg JR, Verweij J, Casali PG et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg. Eur J Cancer 2005; 41: 1751-1757.
15. Van Glabbeke M, Verweij J, Casali PG et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23: 5795-5804.
16. Debiec-Rychter M, Sciot R, LeCesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-1103.
17. Heinrich MC, Corless CL, Blanke CD et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006.
18. Abrams TJ, Lee LB, Murray LJ et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-478.
19. Kim DW, Jo YS, Jung HS et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006; 91: 4070-4076.
20. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
21. Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20: 757-766.
22. O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605.
23. Osusky KL, Hallahan DE, Fu A et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004; 7: 225-233.
24. Schueneman AJ, Himmelfarb E, Geng L et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003; 63: 4009-4016.
25. Heinrich MC, Maki R, Corless CL. Sunitiniti (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. Presented at the 42nd annual meeting of the American Society for Clinical Oncology, Atlanta, GA: 2-6 June, 2006.
26. Morgan JA, Demetri GD, Fletcher JA et al. Durable responses to SU11248 (sunitinib malate) are observed across all genotypes of imatinib mesylate-resistant GIST. Presented at the 17th International Congress on Anti Cancer Treatment. Paris: France, Jan 30-Feb 2, 2006.
27. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006; 368: 1329-1338.
28. Judson I, Casali P, Garrett C et al. Updated results from a phase III trial of sunitinib in advanced gastrointestinal stromal tumuor (GIST). Ann Oncol 2006; 17 (Suppl 9): Ix162.
29. Casali PG, Garrett CR, Blackstein ME et al. Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. Presented at the 42nd annual meeting of the American Society for Clinical Oncology, Atlanta: GA, June 2-6, 2006.
30. Dileo P, Morgan JA, Garrett C et al. Updated results from a "treatment-use" trial of sunitinib in advanced gastrointestinal stromal tumor (GIST). Presented at the 31st congress for the European Society for Medical Oncology. Istanbul: Turkey, Sept 29-Oct 3. 2006.
31. Blay JY, George S, Casali P et al. Clinical benefit of continuous daily dosing of sunitinib in patients (pts) with advanced gastrointestinal stromal tumor (GIST). Presented at the 31st congress for the European Society for Medical Oncology. Istanbul: Turkey, Sept 29-Oct 3, 2006.